Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q3 2021 · 10-Q
Revenue$8.12M$8.12M+24.0% vs Q3 2020 Net Income-$15.45M-$15.45MN/M vs Q3 2020 EPS Diluted-$0.36-$0.36N/M vs Q3 2020 Operating Income-$15,598,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$15,230,000N/M Margins · derivedOperating margin-192.0%−44.0 pt vs Q3 2020
Net margin-190.1%−55.0 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 10, 2021 · 41 d after period end